Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from ...

Hims argued that the agency ignored the company’s disclosures and misapplied federal law on subscriptions and privacy.

Online healthcare provider Hims Hers Health ($HIMS) asked a federal judge to dismiss a lawsuit that accuses the company of ...

Street Target: ~$31__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?Hims & Hers Health (HIMS) has barely moved ...

Hims is a well-known provider in the online hair loss treatment space, offering a variety of hair growth medications in oral and topical forms. Most medications available on the Hims platform are ...

The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances.

Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, ...

Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new ...

If you purchased or acquired Hims securities between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa ...

The lawsuit is focused on the propriety of Hims' repeated assurances that "[w]e have developed and maintain policies and procedures with respect to health information and personal information that we ...

Target Price (Mid): ~$27Street Target: ~$31Potential Total Return: ~(13%)Annualized IRR: ~(3%) / yearWhat Happened?Hims & ...